Quarterly guidance

Quarterly guidance
No specific quarterly guidance was given, though the company maintained its 4% organic revenue growth outlook for the fourth quarter.

Annual guidance

Revenue
$47.7 billion to $48.2 billion
Adjusted EPS
$25.13 to $25.43 per share
Organic revenue growth
4%
Free cash flow
$7 billion to $7.5 billion

Outlook

Pharma and biotech demand
Management sees continued strengthening in this market, driven by improved customer confidence and investment cycles.
AI adoption
The company views AI as a driver of customer ROI, which creates a virtuous cycle of increased demand for products and services.
End-market conditions
The improved conditions observed in Q2 continued into Q3, with strong customer activity across key segments.
Capital deployment
The company continues to execute a disciplined strategy of strategic M&A and returning capital to shareholders.
Bioproduction
The business is expected to be a high single-digit to low double-digit growth business in the long term.